



ANNUAL CONFERENCE ON EU LAW IN THE PHARMACEUTICAL SECTOR 2019

- Competition and intellectual property law
- Medical data and innovative technologies
- Access to medicines in the context of Brexit

Brussels, 21-22 February 2019



Pharmaceutical Law



Speakers

Rainer Becker, Head of Unit, DG COMP, European Commission, Brussels

Peter Bogaert, Partner, Covington & Burling, Brussels

Martin Fitzgerald, Deputy Director General, GIRP (European Healthcare Distribution Association), Brussels

Edith Frénoy, Director, Market Access/HTA, European Federation of Pharmaceutical Industries and Associations (EFPIA), Brussels

Leslie Galloway, Chairman, EMIG (Ethical Medicines Industry group), London

Emmanuelle Huck, Programme/Policy Officer, DG CNECT, European Commission, Brussels

Catherine Longeval, Partner, Van Bael & Bellis, Brussels

Lokke Moerel, Professor, University of Tilburg, Senior Of Counsel, Morrison & Foerster, Berlin

Ingo Müller, Lawyer, Kohlpharma, Merzig

Alexander Natz, Secretary General, EUCOPE, Brussels

Jörg Plessi, Director, EU Affiliates, Regulatory Affairs, Norgine, Wettenberg

Christian Tillmanns, Partner, Meisterernst Rechstanwälte, Munich

Laura Whiting, Counsel, Freshfields Bruckhaus Deringer, London

Key topics

Competition law

Recent rulings from the CJEU and ongoing European Commission cases on pay for delay, off-label use and more

Patent law

SPC manufacturing waiver, specific mechanism for parallel imports

Data exclusivity

Revised EU definition of similar orphan designations, impact of recent General Court rulings on significant benefit

Emerging legal issues linked to new technologies and Digital Health
3-D printing and artificial intelligence, medical data, data sharing and "personalised medicines"

EU pharmaceutical law round-up Recent developments on pricing and access to medicines, HTA post 2020, Brexit "preparedness"

Language English

Event number 219R05

Organiser Florence Hartmann-Vareilles (ERA)



With the support of the Erasmus+ programme of the European Union

ANNUAL CONFERENCE ON EU LAW IN THE PHARMACEUTICAL SECTOR 2019

Thursday, 21 February 2019

09:00 Arrival and registration of participants

09:15 **Opening of the conference** Florence Hartmann-Vareilles

COMPETITION LAW IN THE PHARMACEUTICAL SECTOR

09:30 Impact of recent rulings from the CJEU and update on Commission cases

- Off-label use and by object restriction: Hoffmann-la-Roche and Novartis
- Lundbeck appeal on pay for delay (case of Citalopram)
- Pending cases before the European Commission

Rainer Becker

10:15 Discussion

I.

II. INTELLECTUAL PROPERTY LAW AND DATA EXCLUSIVITY

10:30 Patents and Supplementary Protection Certificates (SPCs)

- Proposal for an EU Regulation on SPC manufacturing waiver
- Combination: what is a product protected by a basic patent?
- Parallel imports and the specific mechanism in light of the CJEU ruling in Orifarm
- Progress on pharmaceutical incentives in the EU

Laura Whiting and Ingo Müller

- 11:30 Discussion
- 11:45 Coffee break

12:15 Data exclusivity and orphan designations

- Similar and biosimilar medicinal products: revised definition adopted by EU Regulation 2018/781
- Significant benefit: impact of recent judgments adopted by the General Court Peter Bogaert
- 13:00 Discussion
- 13:15 Lunch

III. DIGITAL HEALTH, EMERGING TECHNOLOGIES AND ACCESS TO MEDICAL DATA

14:30 Ethical aspects linked to the collection, use and transfer of large amounts of medical data

Lokke Moerel

- 15:00 Discussion
- 15:30 Artificial intelligence, machine-learning and 3-D printing and the need for an EU legal framework
 - Progress and expectations of AI in the life-science sector
 - Legal aspects linked to Al in the health sector
 - Is the EU reform of the medical device legal framework already out of date?
 Christian Tillmanns
- 16:30 Discussion
- 16:45 Coffee break

Objective

This annual conference will bring legal practitioners working with the pharmaceutical sector up-to-date on the latest relevant regulatory developments, legislative initiatives and case law.

Who should attend?

In-house counsel, lawyers in private practice, lawyers in national ministries and authorities dealing with regulation of the sector

You will learn...

- What conclusions can be drawn from recent judgments of the CJEU on competition law in the pharmaceutical sector?
- When can a combination product be protected under patent law according to the CJEU's recent case law?
- How is the specific mechanism applied for parallel imports of medicines?
- What are the new EU rules for data exclusivity of orphan designations?
- What are the legal loopholes faced by the use of artificial intelligence in the life-science sector?
- What are the legal and ethical implications of sharing medical data in the EU?
- On which conditions can a Member State reimburse a medicinal product for indications not covered by an AMM?
- How to prepare for Brexit?

What participants liked in 2018

- ...experienced speakers, topics are chosen well
- ...useful and practical information
- ...interesting discussions and great networking opportunities

Your contact persons



Florence Hartmann-Vareilles Head of Section E-Mail: fhartmann@era.int



Johanna Klaas Assistant E-Mail: jklaas@era.int



17:15 Access to digital data in the European Union: impact on the pharmaceutical and health sectors

- EU initiatives on access and sharing of data
- Legal implications related to access and transfer of medical data
- Future data flows between the UK and the EU after Brexit

Emmanuelle Huck

- 17:45 Discussion
- 18:00 End of the first conference day
- 18:15 Reception

Friday, 22 February 2019

IV. PRICING AND REIMBURSEMENT OF MEDICINAL PRODUCTS FOR HUMAN USE

09:00 Off-label use: impact of the CJEU decision Avastin /Lucentis

Catherine Longeval

09:30 Discussion

09:45 Access to medicines and reimbursement issues

- Guidelines from the European Commission on shortage/ exports to Members States
- HTA: future approach post-2020
- · Gene therapy and innovative payment models

Edith Frénoy, Alexander Natz

- 10:45 Discussion
- 11:00 Coffee break

V. IMPACT OF BREXIT ON THE HEALTH AND PHARMACEUTICAL SECTORS

11:30 Brexit "preparedness check"

Jörg Plessl, Martin Fitzgerald, Leslie Galloway

- 12:30 Discussion
- 13:00 End of conference

For programme updates: **www.era.int**Programme may be subject to amendment.

CPD

ERA's programmes meet the standard requirements for recognition as Continuing Professional Development (CPD). This event corresponds to **9 CPD hours**.

Save the date

The EU Trade Secrets Directive Brussels, 6 December 2018

Three Months to Brexit – Where Do We Stand?

Brussels, 6-7 December 2018

Annual Conference on EU Trade Marks and Designs in Europe 2019

Trier, 28-29 March 2019

Annual Conference on European Data Protection Law 2019

Brussels, 28-29 March 2019

EU State Aid Proceedings and Litigation Brussels, 23-24 May 2019 2018

Summer Course on European Intellectual Property Law Trier, 1-5 July 2019

e-Presentations

Recent Rulings of the General Court in EMA Access to Documents Cases
Aleksandar Rusanov, March 2018

Access to Documents in the EU in the field of Pharmaceutical Law – Recent CJEU Rulings

Brian Kelly, March 2018

Recent EU Developments on Patent Licence Agreements: Lessons Learned from the General Court's *Lundbeck* Ruling on Patent Settlement Agreements

Ingrid Vandenborre, February 2017

Recent EU Developments on Patent Licence Agreements: Genentech v Hoescht (C-567/14)

Marleen H.J. van den Horst, February 2017

www.era.int/elearning

Registration

Annual Conference on EU Law in the Pharmaceutical Sector 2019

Brussels, 22-23 February 2019 / Event Number: 219R05



Europäische Rechtsakademie Academy of European Law Académie de Droit Européen Accademia di Diritto Europeo

Registration

					Fax: +49 (0) 651 93737-773
I would like to register for the ERA event mentioned above. □ Please update my address (see below) □ My address (above) is correct □ Please delete my address PLEASE USE BLOCK CAPITALS:					E-mail: info@era.int Online registration: www.era.int/?128326&en
Title First Name	□ Ms	□ Mr	Other		Postal address: ERA Postfach 1640 D-54206 Trier
Surname					J
Organisation					Location
Position	Tel.				Rue de l'Aqueduc 118 1050 Brussels Belgium
Department E-Mail			 		Language English
Street					Contact Person Johanna Klaas
Postcode/City				Country	Assistant jklaas@era.int
□ Evening pro	gramme: I sh	all attend the	function on Thur	rsday, 21 February (at no extra charge).	+49 651 9 37 37-223 Hotel Recommendations
Registration	n fee			* EU and ERA Patrons	Four Points (Sheraton) Hotel
Fee	Standard	EU & ERA patrons*	Young lawyers & other groups**	Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Romania,	www.fourpointsbrussels.com fourpoints.brussels@starwoodhotels.com Manos Stephanie Hotel www.manosstephanie.com stay@manosstephanie.com
Registration by 21/01/2019	€ 801.00	€ 480.60	€ 600.75	Slovakia, Slovenia, Spain, Sweden, United Kingdom), the German States, Scotland and the City of Trier Fellows of the European Law Institute	Hotel Made in Louise
Registration after 21/01/2019	€ 890.00	€ 534.00	€ 667.50	** Young lawyers & other groups • For young lawyers up to 30 years of age (important: the participant must provide a copy or details of his or her passport or identity card on registration); • Full-time staff of universities or comparable academic institutions; • Staff of charitable organisations or comparable institutions • Registration of three or more employees from the same organisation	www.madeinlouise.com info@madeinlouise.com Please contact the hotel directly to make your reservation.
Method of	payment	:			
☐ Credit card	For reg	gistration with	credit card paym		
☐ Cheque	Cheque number				
☐ Bank transfe	r				
I will transfer the registration fee to ERA's account at Deutsche Bundesbank Saarbrücken: IBAN: DE145900 00 00 00 58501900 – BIC: MARKDEF1590					
Important! Plea	ise state you	r name and t	he event numbe	er on the bank transfer.	

I confirm my registration and accept the general terms and conditions: www.era.int/legalnotice